IRCT20190303042905N3 IRCT 2021-06-22 Tabriz University of Medical Sciences The Effects of sodium butyrate supplementation on obesity The Effects of butyrate supplementation on plasma atherogenic index(AIP), serum level of hsCRP, expression level of adiponectin receptors(AdipoR1& R2), AMP activated protein kinase(AMPK) and uncoupling proteins(UCP2&3) genes in Obese individuals on a weight loss diet: A Randomized, Triple- Blind, Placebo- Controlled Clinical Trial 2021-06-27 anticipated 50 Complete https://irct.ir/trial/56967 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Based on inclusion criteria, 50 patients will randomly allocated to placebo (n = 25) or intervention (n = 25) groups. Block design based on the combined analysis and using random allocation software(RAS)is used for randomization. In fact, according to the pattern and using two codes of A and B 6 groups with 4 blocks are selected. This work is repeated in 2 steps. In the end, two A and B codes are assigned to the 2 last patients and the randomization iscompleted (50 patients), Blinding description: The researchers and patients will not inform of the contents of the packets. A third person of health care does the coding. This person will not aware of the details of the research trial. 2 Obesity. Intervention 1: Intervention group: one butyrate capsule of 600mg/day(made by Body Bio company, USA, containing 550 mg of butyrate and 50 mg sodium hydroxide, medium-chain triglycerides (MCT), hydroxypropyl methylcellulose, and purified water) for 60 days. Intervention 2: Control group: Control group: one placebo capsule of 600 mg/day(compounds similar to supplement except for butyrate). No - There is not a plan to make this available Justification or reason for not sharing IPD is The person's information will be confidential and the results will be as collective statistics